美国FDA批准Rezurock(belumosudil)上市，用于治疗12岁以上的慢性移植物抗宿主病(cGVHD)患者
NEW YORK, NY / ACCESSWIRE / July 16, 2021 - Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved REZUROCK™ (belumosudil) 200 mg once daily (QD) for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.
